Pharma
Pharma

Sun Pharma’s earnings pace is likely to slow down as it takes two steps back for a leap forward

Sun Pharma’s earnings pace is likely to slow down as it takes two steps back for a leap forward

A bird flies past the logo of Sun Pharma installed on the facade of its corporate office in Mumbai, India.

Synopsis

Dilip Shanghvi’s Sun Pharma made a bold move entering the specialty-drugs business which has started to pay it back. Now, the company is scouting acquisitions and augmenting its in-house R&D to enhance its specialty-drugs pipeline. This investment phase may come at the expense of profitability, but for how long?

By
8 mins read, Last Updated:
Dilip Shanghvi has silenced the sceptics. People were unsure about what Shanghvi, founder and managing director of India’s largest pharmaceutical company, Sun Pharmaceutical Industries (Sun Pharma), was up to with his company’s foray in 2013 into the specialty-drugs business. Many questioned the company’s ability to crack the business. But despite the brickbats, the company invested at least USD1.6 billion in the specialty-drugs business over

To Read the Full Story, Become an ET Prime Member

Access the exclusive Economic Times stories, Editorial and Expert opinion

Subscribe Now

Monsoon Offer

Get flat 20% off

on ETPrime membership

Membership Benefits

Access the exclusive Economic Times

Stories, Editorial & Expert opinion

Complete Access with ET Prime

Experience your Economic Times newspaper, The way you've always liked!

Get to know where the market gurus invest & grow your portfolio.

Stock Report Plus

In-depth stock analysis for 4000+ companies

Stock Analyzer

Instant stock analysis based on Solvency, Profitability, Growth, Valuation, Momentum, Risk & More.

Now Available with ET Prime

Manage your money efficiently with this weekly guide.

Clean experience

with minimal ads

Easy & distraction-free reading with 90% less ads

Sharp Insight-rich,

In-depth stories across 20+ sectors

1500+ Exclusive stories & analysis across sectors to help you stay informed

Get One Year Times Prime Subscription worth ₹1199 for free

Get 1 Year Complimentary Subscription of TOI+ worth Rs.799/-

Enjoy unlimited access to breaking news and thought provoking stories from all around the world.

Get One Year Docubay Subscription worth ₹999 for free

Stream award-winning international documentaries from more than 100 countries.

Offers By Our Partners

Exclusively for ET Prime Members

Members Love Us

The stalwarts of the industry trust ET Prime for insightful analysis & unbiased thought pieces

Gift a story

Your membership includes Story Gifting Credits. Now gift exclusive stories to your friends & peers.

Comment & Engage

with ET Prime community

Communicate & build a connection with great minds of the industry

A trusted team of

Journalists & Analysts

Unbiased perspective & detailed reporting by our team of journalists who have in-depth knowledge and years of experience